image
Healthcare - Biotechnology - NASDAQ - DE
$ 95.53
-6.29 %
$ 23 B
Market Cap
-26.24
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one BNTX stock under the worst case scenario is HIDDEN Compared to the current market price of 95.5 USD, BioNTech SE is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one BNTX stock under the base case scenario is HIDDEN Compared to the current market price of 95.5 USD, BioNTech SE is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one BNTX stock under the best case scenario is HIDDEN Compared to the current market price of 95.5 USD, BioNTech SE is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BNTX

image
$130.0$130.0$125.0$125.0$120.0$120.0$115.0$115.0$110.0$110.0$105.0$105.0$100.0$100.0$95.0$95.0$90.0$90.0$85.0$85.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
2.75 B REVENUE
-27.96%
-1.31 B OPERATING INCOME
-190.37%
-678 M NET INCOME
-57.14%
208 M OPERATING CASH FLOW
-96.13%
-2.08 B INVESTING CASH FLOW
70.07%
-45.9 M FINANCING CASH FLOW
94.10%
1.19 B REVENUE
-3.11%
149 M OPERATING INCOME
1315.24%
301 M NET INCOME
54.10%
-463 M OPERATING CASH FLOW
25.01%
607 M INVESTING CASH FLOW
526.95%
-7.3 M FINANCING CASH FLOW
7.59%
Balance Sheet BioNTech SE
image
Current Assets 18.8 B
Cash & Short-Term Investments 16.8 B
Receivables 1.52 B
Other Current Assets 496 M
Non-Current Assets 3.73 B
Long-Term Investments 1.25 B
PP&E 1.18 B
Other Non-Current Assets 1.29 B
74.50 %6.76 %5.57 %5.25 %5.72 %Total Assets$22.5b
Current Liabilities 2.52 B
Accounts Payable 427 M
Short-Term Debt 39.5 M
Other Current Liabilities 2.06 B
Non-Current Liabilities 595 M
Long-Term Debt 215 M
Other Non-Current Liabilities 381 M
13.68 %65.96 %6.88 %12.21 %Total Liabilities$3.1b
EFFICIENCY
Earnings Waterfall BioNTech SE
image
Revenue 2.75 B
Cost Of Revenue 541 M
Gross Profit 2.21 B
Operating Expenses 3.52 B
Operating Income -1.31 B
Other Expenses -637 M
Net Income -678 M
3b3b3b3b2b2b2b2b1b1b500m500m00(500m)(500m)(1b)(1b)(1b)(1b)3b(541m)2b(4b)(1b)637m(678m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
80.32% GROSS MARGIN
80.32%
-47.77% OPERATING MARGIN
-47.77%
-24.18% NET MARGIN
-24.18%
-3.43% ROE
-3.43%
-2.95% ROA
-2.95%
-6.44% ROIC
-6.44%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis BioNTech SE
image
14b14b12b12b10b10b8b8b6b6b4b4b2b2b00(2b)(2b)2018201820192019202020202021202120222022202320232024202420252025
Net Income -678 M
Depreciation & Amortization 298 M
Capital Expenditures -452 M
Stock-Based Compensation 101 M
Change in Working Capital 1.22 B
Others -734 M
Free Cash Flow -245 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets BioNTech SE
image
Wall Street analysts predict an average 1-year price target for BNTX of $123 , with forecasts ranging from a low of $93 to a high of $150 .
BNTX Lowest Price Target Wall Street Target
93 USD -2.65%
BNTX Average Price Target Wall Street Target
123 USD 28.59%
BNTX Highest Price Target Wall Street Target
150 USD 57.02%
Price
Max Price Target
Min Price Target
Average Price Target
150150140140130130120120110110100100909080807070Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
2.11 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
2.5002.5002.0002.0001.5001.5001.0001.0000.5000.5000.0000.0002.1112.1120222022
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership BioNTech SE
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Why BioNTech Stock Got Trounced on Tuesday An unhealthy combination of factors resulted in an unhealthy day on the stock market for next-generation healthcare company BioNTech (BNTX -6.58%). Investors were concerned about the latest top-level appointment in public health, plus an analyst became a bit more bearish about the company's future. fool.com - 2 weeks ago
BioNTech: mRNA Challenges Amid Regulatory Uncertainty (Rating Downgrade) BioNTech maintains strong cash reserves (€15.85B) despite widening losses as COVID revenues decline and R&D expenses increase. BNT327 (PD-L1/VEGF-A bispecific) advances to Phase 3 trials, but shares dropped after competitor's interim data disappointed investors. Increased regulatory scrutiny under Kennedy's HHS creates uncertainty for mRNA technologies, prompting a downgrade from Buy to Hold. seekingalpha.com - 2 weeks ago
BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion BioNTech SE  BNTX on Monday reported a first-quarter per-share loss of $1.82 (1.73 euros), up from 1.31 euros reported a year ago compared to beating the consensus of $2.02. benzinga.com - 2 weeks ago
BioNTech SE (BNTX) Q1 2025 Earnings Call Transcript BioNTech SE (NASDAQ:BNTX ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Co-Founder & Chief Executive Officer Özlem Türeci - Co-Founder & Chief Medical Officer Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Daina Graybosch - Leerink Partners Cory Kasimov - Evercore Terence Flynn - Morgan Stanley Jessica Fye - JPMorgan Evan Seigerman - BMO Capital Markets Yaron Werber - TD Cowen Mohit Bansal - Wells Fargo Harry Gillis - Berenberg John Newman - Canaccord Genuity Operator Welcome to BioNTech's First Quarter 2025 Earnings Call. I would like to hand the call over to Michael Horowicz, Director, Investor Relations. seekingalpha.com - 2 weeks ago
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A 1 , and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech's combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates (“ADCs”) Development and commercial preparation for a 2025/2026 season variant-adapted COVID-19 vaccine First quarter 2025 revenues of €0.2 billion 2 , net loss of €0.4 billion and basic and diluted loss per share of €1.73 ($1.823) Maintained strong financial position with €15.9 billion in cash, cash equivalents and security investments as of March 31, 20254 Full year 2025 financial guidance confirmed Conference call and webcast scheduled for May 5, 2025, at 8:00 a.m. EDT (2:00 p.m. globenewswire.com - 2 weeks ago
BioNTech says Novartis executive Zapata-Gomez to become CFO German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1. reuters.com - 2 weeks ago
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, 2025. He will join BioNTech from Novartis AG's global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term on June 30, 2025. globenewswire.com - 2 weeks ago
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (SMMT -36.19%) and BioNTech (BNTX -15.40%) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading. fool.com - 3 weeks ago
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association for Cancer Research (“AACR”) Annual Meeting held in Chicago, Illinois from April 25-30, 2025. The oral and poster presentations underline both the progress of BioNTech's advanced priority oncology programs as well as the execution of the Company's combination strategy in oncology, with first data to be presented for the combination of the PD-L1xVEGF-A bispecific antibody candidate BNT3271 plus antibody-drug conjugates (“ADCs”). globenewswire.com - 3 weeks ago
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025 MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. globenewswire.com - 4 weeks ago
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength? BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. zacks.com - 1 month ago
Vaccine stocks fall following FDA resignation Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more. youtube.com - 1 month ago
8. Profile Summary

BioNTech SE BNTX

image
COUNTRY DE
INDUSTRY Biotechnology
MARKET CAP $ 23 B
Dividend Yield 0.00%
Description BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Contact An der Goldgrube 12, Mainz, 55131 https://www.biontech.de
IPO Date Oct. 10, 2019
Employees 6772
Officers Ms. Beate Berns Senior Vice President of Global Human Resources Dr. Ugur Sahin M.D. Co-Founder, Chief Executive Officer & Chair of the Management Board Dr. Ozlem Tureci M.D. Co-Founder, Chief Medical Officer & Member of Management Board Mr. Jens H. Holstein Chief Financial Officer & Member of Management Board Dr. Sierk Poetting Ph.D. MD, Chief Operating Officer & Member of Management Board Ms. Lisa Birringer Senior Vice President of Global Financial Reporting & Accounting Dr. James Timothy Patrick Ryan Ph.D. Chief Legal & Business Officer & Member of the Management Board Mr. Zach Taylor Senior Vice President of Corporate Development & Strategy Mr. Ryan Richardson Chief Strategy Officer, MD & Member of Management Board Ms. Annemarie Hanekamp Chief Commercial Officer & Member of Management Board